|Podcasts|February 14, 2019

Episode 25: China’s Pharma Growth

Author(s)Michelle Maskaly, Christen Harm

Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 26th, 2026

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

October 26th, 2026

The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki

Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

October 23rd, 2026

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.

October 23rd, 2026

Building Biopharma Manufacturing for Speed, Scale, and Flexibility

Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

October 20th, 2026

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.

October 19th, 2026

Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs

Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.

Trending on PharmExec

The Next Biopharma Revolution: Quantum Computing

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

Episode 25: China’s Pharma Growth

Related to this article

Trending on PharmExec

The Next Biopharma Revolution: Quantum Computing

Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific

How Medications like XOCOVA Prevent Illness After Exposure to COVID-19

Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin

Caution and Pharma’s AI Adoption: Understanding the Reasons Behind Uneven Uptake